Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis
Murine double minute 2 (MDM2) plays an important role in the carcinogenesis of many cancers including osteosarcoma. We performed a systemic review and meta-analysis to assess the effects of MDM2 polymorphisms on osteosarcoma risk and survival of patients with osteosarcoma. PubMed, Web of Science, an...
Gespeichert in:
| Veröffentlicht in: | Tumor biology 2014-02, Vol.35 (2), p.1649-1652 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1652 |
|---|---|
| container_issue | 2 |
| container_start_page | 1649 |
| container_title | Tumor biology |
| container_volume | 35 |
| creator | Wang, Lichun Liu, Zehan Jing, Pengwei Shao, Lin Chen, Lin He, Xu Gong, Weixun |
| description | Murine double minute 2 (MDM2) plays an important role in the carcinogenesis of many cancers including osteosarcoma. We performed a systemic review and meta-analysis to assess the effects of MDM2 polymorphisms on osteosarcoma risk and survival of patients with osteosarcoma. PubMed, Web of Science, and Wanfang databases were searched for eligible studies on the associations of MDM2 polymorphisms with osteosarcoma risk and survival of patients with osteosarcoma. Pooled odds ratio (OR) or hazard ratio (HR) with 95 % confidence intervals (95 % CIs) was used to assess the effects of MDM2 polymorphisms on osteosarcoma risk and survival of patients with osteosarcoma. Overall, MDM2 rs2279744 polymorphism was associated with a risk of osteosarcoma (allele model, OR = 1.60, 95 % CI 1.23–2.07,
P
|
| doi_str_mv | 10.1007/s13277-013-1227-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1501014971</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3226484731</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-1714b42f920004678db50b41ec4964ac6246ba99d3c77e6f28fc6c3ac894eff03</originalsourceid><addsrcrecordid>eNp1kM1u3CAUhVHUqvl9gG4qpK5JLj9j7O6qKG0iRcomXSOMISE1Zsq1p5pF3r1MJ62yyQoE3zn36iPkI4dzDqAvkEuhNQMuGRdCs_aAHHElJAPZwrt6Bw5MiVYekmPEJwC-6rrmAzkUqvICxBF5vgrBuxlpDjQtJU6eDnnpR09TnJbZU0HXedymXNaPEVPlJjo_eloi_qR2GiguZRM3dtwVZJx9RltcTvYLtRS39SFFR4vfRP_7L5_8bJmd7LjFiKfkfbAj-rOX84T8-HZ1f3nNbu--31x-vWVOajEzrrnqlQidAADV6HboV9Ar7p3qGmVdI1TT264bpNPaN0G0wTVOWtd2yocA8oR83veuS_61eJzNU15KXQINX1VJXHWaV4rvKVcyYvHBrEtMtmwNB7MTbvbCTRVudsJNWzOfXpqXPvnhf-Kf4QqIPYD1a3rw5dXoN1v_ADCAjGE</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1501014971</pqid></control><display><type>article</type><title>Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis</title><source>MEDLINE</source><source>SpringerNature Journals</source><creator>Wang, Lichun ; Liu, Zehan ; Jing, Pengwei ; Shao, Lin ; Chen, Lin ; He, Xu ; Gong, Weixun</creator><creatorcontrib>Wang, Lichun ; Liu, Zehan ; Jing, Pengwei ; Shao, Lin ; Chen, Lin ; He, Xu ; Gong, Weixun</creatorcontrib><description>Murine double minute 2 (MDM2) plays an important role in the carcinogenesis of many cancers including osteosarcoma. We performed a systemic review and meta-analysis to assess the effects of MDM2 polymorphisms on osteosarcoma risk and survival of patients with osteosarcoma. PubMed, Web of Science, and Wanfang databases were searched for eligible studies on the associations of MDM2 polymorphisms with osteosarcoma risk and survival of patients with osteosarcoma. Pooled odds ratio (OR) or hazard ratio (HR) with 95 % confidence intervals (95 % CIs) was used to assess the effects of MDM2 polymorphisms on osteosarcoma risk and survival of patients with osteosarcoma. Overall, MDM2 rs2279744 polymorphism was associated with a risk of osteosarcoma (allele model, OR = 1.60, 95 % CI 1.23–2.07,
P
< 0.001; codominant model, OR = 2.47, 95 % CI 1.46–4.19,
P
= 0.001; recessive model, OR = 2.13, 95 % CI 1.32–3.46,
P
= 0.002; dominant model, OR = 1.61, 95 % CI 1.12–2.33,
P
= 0.01). MDM2 rs1690916 polymorphism was also associated with a risk of osteosarcoma (OR = 0.60, 95 % CI 0.46–0.77,
P
< 0.001). However, MDM2 rs2279744 polymorphism was not associated with the overall survival of patients with osteosarcoma (codominant model, HR = 1.01, 95 % CI 0.53–1.91,
P
= 0.98; recessive model, HR = 1.07, 95 % CI 0.54–2.11,
P
= 0.85; dominant model, HR = 1.04, 95 % CI 0.65–1.66,
P
= 0.87). The meta-analysis suggests that MDM2 polymorphisms have some effects on the risk of osteosarcoma but have no effect on the survival of patients with osteosarcoma. Future studies are needed to further assess the effects of MDM2 polymorphisms on the risk and survival of osteosarcoma.</description><identifier>ISSN: 1010-4283</identifier><identifier>EISSN: 1423-0380</identifier><identifier>DOI: 10.1007/s13277-013-1227-8</identifier><identifier>PMID: 24122202</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Animals ; Biomedical and Life Sciences ; Biomedicine ; Bone cancer ; Bone Neoplasms - genetics ; Bone Neoplasms - mortality ; Bone Neoplasms - pathology ; Cancer Research ; Genes ; Genetic Association Studies ; Genetic Predisposition to Disease ; Humans ; Mice ; Osteosarcoma - genetics ; Osteosarcoma - mortality ; Osteosarcoma - pathology ; Polymorphism ; Polymorphism, Single Nucleotide ; Proto-Oncogene Proteins c-mdm2 - genetics ; Research Article ; Risk Factors ; Survival Analysis ; Systematic review</subject><ispartof>Tumor biology, 2014-02, Vol.35 (2), p.1649-1652</ispartof><rights>International Society of Oncology and BioMarkers (ISOBM) 2013</rights><rights>International Society of Oncology and BioMarkers (ISOBM) 2014</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-1714b42f920004678db50b41ec4964ac6246ba99d3c77e6f28fc6c3ac894eff03</citedby><cites>FETCH-LOGICAL-c372t-1714b42f920004678db50b41ec4964ac6246ba99d3c77e6f28fc6c3ac894eff03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s13277-013-1227-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s13277-013-1227-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>315,781,785,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24122202$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Lichun</creatorcontrib><creatorcontrib>Liu, Zehan</creatorcontrib><creatorcontrib>Jing, Pengwei</creatorcontrib><creatorcontrib>Shao, Lin</creatorcontrib><creatorcontrib>Chen, Lin</creatorcontrib><creatorcontrib>He, Xu</creatorcontrib><creatorcontrib>Gong, Weixun</creatorcontrib><title>Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis</title><title>Tumor biology</title><addtitle>Tumor Biol</addtitle><addtitle>Tumour Biol</addtitle><description>Murine double minute 2 (MDM2) plays an important role in the carcinogenesis of many cancers including osteosarcoma. We performed a systemic review and meta-analysis to assess the effects of MDM2 polymorphisms on osteosarcoma risk and survival of patients with osteosarcoma. PubMed, Web of Science, and Wanfang databases were searched for eligible studies on the associations of MDM2 polymorphisms with osteosarcoma risk and survival of patients with osteosarcoma. Pooled odds ratio (OR) or hazard ratio (HR) with 95 % confidence intervals (95 % CIs) was used to assess the effects of MDM2 polymorphisms on osteosarcoma risk and survival of patients with osteosarcoma. Overall, MDM2 rs2279744 polymorphism was associated with a risk of osteosarcoma (allele model, OR = 1.60, 95 % CI 1.23–2.07,
P
< 0.001; codominant model, OR = 2.47, 95 % CI 1.46–4.19,
P
= 0.001; recessive model, OR = 2.13, 95 % CI 1.32–3.46,
P
= 0.002; dominant model, OR = 1.61, 95 % CI 1.12–2.33,
P
= 0.01). MDM2 rs1690916 polymorphism was also associated with a risk of osteosarcoma (OR = 0.60, 95 % CI 0.46–0.77,
P
< 0.001). However, MDM2 rs2279744 polymorphism was not associated with the overall survival of patients with osteosarcoma (codominant model, HR = 1.01, 95 % CI 0.53–1.91,
P
= 0.98; recessive model, HR = 1.07, 95 % CI 0.54–2.11,
P
= 0.85; dominant model, HR = 1.04, 95 % CI 0.65–1.66,
P
= 0.87). The meta-analysis suggests that MDM2 polymorphisms have some effects on the risk of osteosarcoma but have no effect on the survival of patients with osteosarcoma. Future studies are needed to further assess the effects of MDM2 polymorphisms on the risk and survival of osteosarcoma.</description><subject>Animals</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bone cancer</subject><subject>Bone Neoplasms - genetics</subject><subject>Bone Neoplasms - mortality</subject><subject>Bone Neoplasms - pathology</subject><subject>Cancer Research</subject><subject>Genes</subject><subject>Genetic Association Studies</subject><subject>Genetic Predisposition to Disease</subject><subject>Humans</subject><subject>Mice</subject><subject>Osteosarcoma - genetics</subject><subject>Osteosarcoma - mortality</subject><subject>Osteosarcoma - pathology</subject><subject>Polymorphism</subject><subject>Polymorphism, Single Nucleotide</subject><subject>Proto-Oncogene Proteins c-mdm2 - genetics</subject><subject>Research Article</subject><subject>Risk Factors</subject><subject>Survival Analysis</subject><subject>Systematic review</subject><issn>1010-4283</issn><issn>1423-0380</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kM1u3CAUhVHUqvl9gG4qpK5JLj9j7O6qKG0iRcomXSOMISE1Zsq1p5pF3r1MJ62yyQoE3zn36iPkI4dzDqAvkEuhNQMuGRdCs_aAHHElJAPZwrt6Bw5MiVYekmPEJwC-6rrmAzkUqvICxBF5vgrBuxlpDjQtJU6eDnnpR09TnJbZU0HXedymXNaPEVPlJjo_eloi_qR2GiguZRM3dtwVZJx9RltcTvYLtRS39SFFR4vfRP_7L5_8bJmd7LjFiKfkfbAj-rOX84T8-HZ1f3nNbu--31x-vWVOajEzrrnqlQidAADV6HboV9Ar7p3qGmVdI1TT264bpNPaN0G0wTVOWtd2yocA8oR83veuS_61eJzNU15KXQINX1VJXHWaV4rvKVcyYvHBrEtMtmwNB7MTbvbCTRVudsJNWzOfXpqXPvnhf-Kf4QqIPYD1a3rw5dXoN1v_ADCAjGE</recordid><startdate>20140201</startdate><enddate>20140201</enddate><creator>Wang, Lichun</creator><creator>Liu, Zehan</creator><creator>Jing, Pengwei</creator><creator>Shao, Lin</creator><creator>Chen, Lin</creator><creator>He, Xu</creator><creator>Gong, Weixun</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope></search><sort><creationdate>20140201</creationdate><title>Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis</title><author>Wang, Lichun ; Liu, Zehan ; Jing, Pengwei ; Shao, Lin ; Chen, Lin ; He, Xu ; Gong, Weixun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-1714b42f920004678db50b41ec4964ac6246ba99d3c77e6f28fc6c3ac894eff03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Animals</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bone cancer</topic><topic>Bone Neoplasms - genetics</topic><topic>Bone Neoplasms - mortality</topic><topic>Bone Neoplasms - pathology</topic><topic>Cancer Research</topic><topic>Genes</topic><topic>Genetic Association Studies</topic><topic>Genetic Predisposition to Disease</topic><topic>Humans</topic><topic>Mice</topic><topic>Osteosarcoma - genetics</topic><topic>Osteosarcoma - mortality</topic><topic>Osteosarcoma - pathology</topic><topic>Polymorphism</topic><topic>Polymorphism, Single Nucleotide</topic><topic>Proto-Oncogene Proteins c-mdm2 - genetics</topic><topic>Research Article</topic><topic>Risk Factors</topic><topic>Survival Analysis</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Lichun</creatorcontrib><creatorcontrib>Liu, Zehan</creatorcontrib><creatorcontrib>Jing, Pengwei</creatorcontrib><creatorcontrib>Shao, Lin</creatorcontrib><creatorcontrib>Chen, Lin</creatorcontrib><creatorcontrib>He, Xu</creatorcontrib><creatorcontrib>Gong, Weixun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection (ProQuest)</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><jtitle>Tumor biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Lichun</au><au>Liu, Zehan</au><au>Jing, Pengwei</au><au>Shao, Lin</au><au>Chen, Lin</au><au>He, Xu</au><au>Gong, Weixun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis</atitle><jtitle>Tumor biology</jtitle><stitle>Tumor Biol</stitle><addtitle>Tumour Biol</addtitle><date>2014-02-01</date><risdate>2014</risdate><volume>35</volume><issue>2</issue><spage>1649</spage><epage>1652</epage><pages>1649-1652</pages><issn>1010-4283</issn><eissn>1423-0380</eissn><abstract>Murine double minute 2 (MDM2) plays an important role in the carcinogenesis of many cancers including osteosarcoma. We performed a systemic review and meta-analysis to assess the effects of MDM2 polymorphisms on osteosarcoma risk and survival of patients with osteosarcoma. PubMed, Web of Science, and Wanfang databases were searched for eligible studies on the associations of MDM2 polymorphisms with osteosarcoma risk and survival of patients with osteosarcoma. Pooled odds ratio (OR) or hazard ratio (HR) with 95 % confidence intervals (95 % CIs) was used to assess the effects of MDM2 polymorphisms on osteosarcoma risk and survival of patients with osteosarcoma. Overall, MDM2 rs2279744 polymorphism was associated with a risk of osteosarcoma (allele model, OR = 1.60, 95 % CI 1.23–2.07,
P
< 0.001; codominant model, OR = 2.47, 95 % CI 1.46–4.19,
P
= 0.001; recessive model, OR = 2.13, 95 % CI 1.32–3.46,
P
= 0.002; dominant model, OR = 1.61, 95 % CI 1.12–2.33,
P
= 0.01). MDM2 rs1690916 polymorphism was also associated with a risk of osteosarcoma (OR = 0.60, 95 % CI 0.46–0.77,
P
< 0.001). However, MDM2 rs2279744 polymorphism was not associated with the overall survival of patients with osteosarcoma (codominant model, HR = 1.01, 95 % CI 0.53–1.91,
P
= 0.98; recessive model, HR = 1.07, 95 % CI 0.54–2.11,
P
= 0.85; dominant model, HR = 1.04, 95 % CI 0.65–1.66,
P
= 0.87). The meta-analysis suggests that MDM2 polymorphisms have some effects on the risk of osteosarcoma but have no effect on the survival of patients with osteosarcoma. Future studies are needed to further assess the effects of MDM2 polymorphisms on the risk and survival of osteosarcoma.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>24122202</pmid><doi>10.1007/s13277-013-1227-8</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1010-4283 |
| ispartof | Tumor biology, 2014-02, Vol.35 (2), p.1649-1652 |
| issn | 1010-4283 1423-0380 |
| language | eng |
| recordid | cdi_proquest_journals_1501014971 |
| source | MEDLINE; SpringerNature Journals |
| subjects | Animals Biomedical and Life Sciences Biomedicine Bone cancer Bone Neoplasms - genetics Bone Neoplasms - mortality Bone Neoplasms - pathology Cancer Research Genes Genetic Association Studies Genetic Predisposition to Disease Humans Mice Osteosarcoma - genetics Osteosarcoma - mortality Osteosarcoma - pathology Polymorphism Polymorphism, Single Nucleotide Proto-Oncogene Proteins c-mdm2 - genetics Research Article Risk Factors Survival Analysis Systematic review |
| title | Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-13T01%3A45%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20murine%20double%20minute%202%20polymorphisms%20on%20the%20risk%20and%20survival%20of%20osteosarcoma:%20a%20systemic%20review%20and%20meta-analysis&rft.jtitle=Tumor%20biology&rft.au=Wang,%20Lichun&rft.date=2014-02-01&rft.volume=35&rft.issue=2&rft.spage=1649&rft.epage=1652&rft.pages=1649-1652&rft.issn=1010-4283&rft.eissn=1423-0380&rft_id=info:doi/10.1007/s13277-013-1227-8&rft_dat=%3Cproquest_cross%3E3226484731%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1501014971&rft_id=info:pmid/24122202&rfr_iscdi=true |